Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.

Human pathology - 1 Oct 2015

Choi Yong Won, Kim Young Hwa, Lee Jeonghun, Soh Euy Young, Park Tae Jun, Kim Jang-Hee

Abstract excerpt

Midkine is a multifunctional, heparin-binding growth factor that is frequently expressed in patients with malignancies but is undetectable in healthy adults. In various cancers, high expression of midkine is associated with aggressive clinical behavior and a poor prognosis. In the present study, we investigated the expression of midkine in papillary thyroid carcinoma (PTC) and assessed its association with a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Carcinoma, Papillary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphatic Metastasis

Share to Nerve Growth Factors

Share to Proto-Oncogene Proteins B-raf

Share to Real-Time Polymerase Chain Reaction

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 26297257
DOI: 10.1016/j.humpath.2015.06.018

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.PMID 26297257Read ↗

Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer.Semantic proximity Read ↗

The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?Semantic proximity Read ↗

Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.Semantic proximity Read ↗

BRAFV600E and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer ProgressionSemantic proximity Read ↗

Overexpression of the pro-protein convertase furin predicts prognosis and promotes papillary thyroid carcinoma progression and metastasis through RAF/MEK signaling.Semantic proximity Read ↗

BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China.Semantic proximity Read ↗

PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by BRAFV600E MutationSemantic proximity Read ↗

Identification of Long Noncoding RNAs Deregulated in Papillary Thyroid Cancer and Correlated with BRAFV600E Mutation by Bioinformatics Integrative Analysis.Semantic proximity Read ↗

Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis.Semantic proximity Read ↗

Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.Semantic proximity Read ↗

BRAFV600E mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features.Semantic proximity Read ↗

Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.